D-0083-2027 Class I Ongoing

Recalled by Par Health USA, LLC — Rochester, MI

FDA drug recall D-0083-2027 was initiated by Par Health USA, LLC on Oct 13, 2026 and is designated Class I. Reason for recall: Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution. The recall status is ongoing. Affected quantity: 1944 vials.

Recall details

Product Type
Drugs
Report Date
Oct 28, 2026
Initiation Date
Oct 13, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1944 vials

Product description

Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/ Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Cranbury, NJ 08512, NDC 42023-182-89.

Reason for recall

Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.

Distribution pattern

Nationwide within the United States

Code information

Lot #: 84193, Exp Date: 10/2026; 92880, Exp Date: 08/2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0083-2027
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0083-2027. Report a data issue: hello@regdatalab.com.